At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ADIL Adial Pharmaceuticals
Closed Good Friday 04-17 16:00:00 EDT
0.6860
-0.0309
-4.31%
盘后0.7298
+0.0438+6.38%
17:28 EDT
| High0.7300 | Low0.6800 | Vol18.50K |
| Open0.7000 | D1 Closing0.7169 | Amplitude6.97% |
| Mkt Cap4.51M | Tradable Cap4.22M | Total Shares6.57M |
| T/O12.92K | T/O Rate0.30% | Tradable Shares6.15M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Adial Pharmaceuticals Appoints Tony Goodman as COO
TIPRANKS · 03-21
Adial Pharmaceuticals FY 2024 GAAP EPS $(2.72) Beats $(2.97) Estimate
Benzinga · 03-04
Adial Pharmaceuticals expects cash to fund operations into 2H of 2025
TIPRANKS · 03-04
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update
GlobeNewswire · 03-04
BUZZ-Adial Pharma jumps on regulatory pathway for alcohol-use disorder drug
Reuters · 02-25
Adial Pharmaceuticals Advances AD04 with FDA Approval
TIPRANKS · 02-25
BRIEF-Adial Pharma Receives Positive Response From FDA Meeting Regarding Vitro Bridging Strategy For AD04
Reuters · 02-25
Adial says FDA feedback confirms proposed strategy to AD04 Phase 3 formulation
TIPRANKS · 02-25
Adial Pharmaceuticals Receives Positive Response From FDA Meeting Regarding Proposed in Vitro Bridging Strategy for Ad04
THOMSON REUTERS · 02-25
Adial Pharmaceuticals- Moves Forward With Manufacturing Clinical Supplies for Phase 3 Program in 2025
THOMSON REUTERS · 02-25
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
GlobeNewswire · 02-25
EXCLUSIVE: After FDA Response, Adial Starts Manufacturing Clinical Supplies For Upcoming Phase 3 Program Of Lead Candidate For Alcohol Use Disorder
Benzinga · 02-25
BRIEF-Adial Pharmaceuticals Granted New U.S. Patent On Method To Identify Genetic Markers In Alcohol or Opioid-Related Disorders
Reuters · 02-19
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of Its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies
THOMSON REUTERS · 02-19
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies
GlobeNewswire · 02-19
Adial Pharmaceuticals awarded new U.S. patent on genotype-specific treatment
TIPRANKS · 02-12
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
THOMSON REUTERS · 02-12
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
GlobeNewswire · 02-12
Adial Pharmaceuticals announce clinical study results from AD04-103 study
TIPRANKS · 01-29
Adial Pharmaceuticals Announces Positive Clinical Study Results From the Ad04-103 Pharmacokinetics Study of Ad04 for the Treatment of Alcohol Use Disorder
THOMSON REUTERS · 01-29
Introduction
Company Name.
Adial Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App